Medscape2d
Cabozantinib Improves PFS in Advanced Neuroendocrine Tumors After Prior Treatment
Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.
Oncology Nurse Advisor19d
Radioembolization Plus Chemo Shows Activity in Liver-Dominant Metastatic NETs
The combination of chemotherapy and radioembolization appeared safe and effective in patients with well-differentiated, liver-dominant, grade 3 NETs.
Medscape20d
Drug Combo for Common Neuroendocrine Tumor: A New Standard?
Adding the somatostatin analog lanreotide to the mTOR inhibitor everolimus significantly prolonged progression-free survival in patients with unresectable or recurrent gastroenteropancreatic ...
ascopubs.org20d
Adjuvant therapy with somatostatin analogs for recurrent gastric neuroendocrine tumors type 1.
Matching adjusted indirect comparison (MAIC) of 177Lu-DOTATATE vs. sunitinib as first-line (1L) treatment for advanced grade 2 (G2) pancreatic neuroendocrine tumors (pNETs). This is an ASCO Meeting ...
Business Wire22d
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO ...
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...
C&EN26d
Preparation, Antifungal Activity Evaluation, and Mechanistic Studies of Unique and Structurally Novel Pyrazole-Heterocyclic-Amide Analogues
School of Science, Asymmetric Synthesis and Chirotechnology Key Laboratory of Sichuan Province, Xihua University, Chengdu 610039, P. R. China ...